• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

蛋白质纯化工艺开发中的分析考量

Analytical considerations in the development of protein purification processes.

作者信息

Anicetti V, Hancock W S

机构信息

Genentech, Inc., South San Francisco, California.

出版信息

Bioprocess Technol. 1994;18:11-36.

PMID:7764169
Abstract

Successful and rapid process development requires the availability of suitable analytical methods at all stages of the development cycle (see Tables 2 and 3). The methods should be selected first to ensure the identity, potency, and purity of the product and second to facilitate the process development. Some assays are particularly valuable early in the recovery process (and early in the development cycle) because they are typically robust and can be used with crude samples that contain many components. Popular examples include SDS-PAGE, IEF, and immunoassay, which allow the process scientist simply to monitor the yield and removal of impurities on a broad scale. Each step should be monitored with a biological assay, so that the specific activity of the target protein can be followed and steps that cause a loss of activity can be quickly detected. At the end of the recovery process (and development cycle) more sophisticated analytical methods, for example RP-HPLC and mass spectrometry, are used to detect and characterize variants of the desired product. Highly process-specific assays, such as host cell impurity ELISAs, are developed at this point, and the key methods for process monitoring and final product characterization are selected. While each process development project is distinct, in all cases the use of well-validated complementary analytical methods will provide greater assurance of a timely and successful project.

摘要

成功且快速的工艺开发要求在开发周期的各个阶段都具备合适的分析方法(见表2和表3)。首先应选择能确保产品的鉴别、效价和纯度的方法,其次应选择有助于工艺开发的方法。有些分析方法在回收过程早期(以及开发周期早期)特别有价值,因为它们通常稳健,可用于含有多种成分的粗样品。常见的例子包括SDS-PAGE、IEF和免疫分析,这些方法能让工艺科学家简单地从宏观上监测产量和杂质去除情况。每一步都应用生物分析进行监测,以便追踪目标蛋白的比活性,并能快速检测出导致活性丧失的步骤。在回收过程结束时(以及开发周期结束时),会使用更复杂的分析方法,如反相高效液相色谱法(RP-HPLC)和质谱分析法,来检测和鉴定所需产品的变体。此时会开发高度针对特定工艺的分析方法,如宿主细胞杂质酶联免疫吸附测定法(ELISA),并选择用于工艺监测和最终产品鉴定的关键方法。虽然每个工艺开发项目都各不相同,但在所有情况下,使用经过充分验证的互补分析方法将更有把握确保项目及时且成功。

相似文献

1
Analytical considerations in the development of protein purification processes.蛋白质纯化工艺开发中的分析考量
Bioprocess Technol. 1994;18:11-36.
2
Validation of biotechnological production processes.生物技术生产工艺的验证
Arzneimittelforschung. 1988 Jun;38(6):855-62.
3
Quality control and analytical techniques for biopharmaceuticals.生物制药的质量控制与分析技术
Bioanalysis. 2011 Jan;3(1):81-95. doi: 10.4155/bio.10.161.
4
The role of assay validation in specification development.分析方法验证在质量标准制定中的作用。
Dev Biol Stand. 1997;91:105-13.
5
Conversion of a CHO cell culture process from perfusion to fed-batch technology without altering product quality.在不改变产品质量的情况下,将CHO细胞培养工艺从灌注技术转换为补料分批技术。
J Biotechnol. 2006 May 3;123(1):106-16. doi: 10.1016/j.jbiotec.2005.10.013. Epub 2005 Dec 1.
6
FDA perspective on specifications for biotechnology products--from IND to PLA.美国食品药品监督管理局对生物技术产品规范的观点——从研究性新药申请到产品许可申请
Dev Biol Stand. 1997;91:3-13.
7
Consistency and stability of recombinant fermentations.重组发酵的一致性和稳定性。
Dev Biol Stand. 1994;83:45-54.
8
Process and product monitoring of recombinant DNA-derived biopharmaceuticals with high-performance capillary electrophoresis.利用高效毛细管电泳对重组DNA衍生生物制药进行过程和产品监测。
J Capill Electrophor Microchip Technol. 2003 Sep-Dec;8(5-6):87-99.
9
Demonstration of robust host cell protein clearance in biopharmaceutical downstream processes.生物制药下游工艺中强大的宿主细胞蛋白清除能力的证明。
Biotechnol Prog. 2008 May-Jun;24(3):615-22. doi: 10.1021/bp070396j. Epub 2008 Apr 15.
10
Quality control of rDNA-derived human tissue-type plasminogen activator.
Bioprocess Technol. 1990;10:543-66.